Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption pathways to allow oral delivery of some drugs previously requiring injection. The research, published in Science Translational Medicine, describes the first clinical evidence that a fat (lipid) modified version of the naturally occurring neurosteroid allopregnanolone (GlyphAllo) can result in high enough levels of the substance in the human bloodstream to be potentially effective.
This article was originally published on MedicalXpress.com
